Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 16.4% from the November 30th total of 49,500 shares. Based on an average daily volume of 170,100 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.9% of the shares of the stock are short sold.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ ADIL opened at $1.03 on Tuesday. The firm’s 50 day moving average price is $1.06 and its 200 day moving average price is $1.05. Adial Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $4.17.

Wall Street Analysts Forecast Growth

ADIL has been the topic of a number of recent research reports. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective on the stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.